港股異動丨李氏大藥廠(00950.HK)漲近5% 擬攜手美國IACTA合作開發IC-265及IC-270
格隆匯5月11日丨李氏大藥廠(00950.HK)漲近5%,報4.21港元,總市值24.76億港元。李氏大藥廠上週五盤後公告,於2020年5月4日,公司間接非全資附屬公司兆科(香港)眼科藥物有限公司與IACTA Pharmaceuticals,Inc.(一間專注眼科藥品的美國醫藥公司,為治療大量醫療需求未得到滿足的疾病而開發新型作用機制的藥物)就於中國及東南亞其他國家開發、製造及商品化IC-265及IC-270的獨家權利訂立一份具法律約束力的意向書。訂約雙方計劃在全球合作開發IC-265及IC-270。此外,於2020年4月28日,公司全資附屬公司李氏香港的Natulan®新藥上市申請已獲國家藥監局受理,該藥物乃用於治療晚期霍奇金淋巴瘤("HL")。預期集團將於2020年5月底前提交新藥申請的優先審評申請。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.